Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02201810 · ClinicalTrials.gov registry record · NA
Enhancing the Efficacy of Smoking Quit Line in the Military (AFIII Renewal)
A NA study, sponsored by University of Virginia.
- Completed
- Registry status
- NA
- Development phase
- 614
- Enrollment target
NCT02201810: Completed NA study, sponsored by University of Virginia.
NCT02201810 is a NA study that has completed, run by University of Virginia. The registered enrollment target is 614 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (56% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02201810, a NA study, has completed, sponsored by University of Virginia.
- COMPLETED
- Registry status
- NA
- Development phase
- 614 participants
- Enrollment target
Study Summary
This study is a randomized clinical trial designed to measure the effectiveness of three QL interventions for smokers who failed to quit an initial smoking cessation intervention, but remain motivated to quit smoking.
Primary Outcome
We will assess tobacco status (both 7-day point prevalence and continuous abstinence) at the follow-up period (one year after reengagement interventions are completed) to assess outcome.
Interventions
- BEHAVIORAL Rate reduction intervention
- BEHAVIORAL Recycling Group
- BEHAVIORAL Choice Group
- BEHAVIORAL Proactive QL
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 614 participants |
| Start Date | 2015-05 |
| Est. Completion | 2020-11-30 |
| Phase | NA |
What the finished NCT02201810 record still lists
NCT02201810 is an interventional study that assigns participants to a tested intervention. The registered 614 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (56% lower).
The record links to 0 conditions, and to 4 interventions - of which Rate reduction intervention is the first listed.
NCT02201810 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02201810 about?
NCT02201810 is a clinical study titled "Enhancing the Efficacy of Smoking Quit Line in the Military (AFIII Renewal)". This study is a randomized clinical trial designed to measure the effectiveness of three QL interventions for smokers who failed to quit an initial smoking cessation intervention, but remain motivated to quit smoking.
What is the current status of trial NCT02201810?
This trial is currently completed. It is a NA study. The enrollment target is 614 participants. The study started on 2015-05. Estimated completion is 2020-11-30.
What interventions are being tested in trial NCT02201810?
The interventions under investigation include: Rate reduction intervention (BEHAVIORAL), Recycling Group (BEHAVIORAL), Choice Group (BEHAVIORAL), Proactive QL (BEHAVIORAL).
Who is sponsoring clinical trial NCT02201810?
This trial is sponsored by University of Virginia, which has 449 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02201810's enrollment target sits among peer trials
614 161st of 2000 higher than 1,840 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03821857 · 614 participants · Phase 4
Sex-Specific Effects of Endocrine Disruption on Aging and Alzheimer's Disease
- NCT05006716 · 614 participants · Phase 1
A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies
- NCT06170788 · 614 participants · Phase 3
Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)
- NCT07409272 · 614 participants · Phase 3
A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia